The Muscular Dystrophies

The muscular dystrophies are disorders of progressive muscular degeneration and weakness. As a group they display clinical heterogeneity that reflects the heterogeneity of molecular mechanisms responsible for them, and range from congenital to adulthood onset. Recent advances in the field include improved methods of diagnosis, continued identification of disease genes, and the development of a unified model of pathogenesis in facioscapulohumeral dystrophy. These advances are reflected in the development of new therapeutic approaches, some of which have already led to clinical trials in the dystrophinopathies and limb-girdle dystrophies.

[1]  N. Romero,et al.  Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype , 2009, Neuromuscular Disorders.

[2]  J. Gilbert,et al.  Myotilin is mutated in limb girdle muscular dystrophy 1A. , 2000, Human molecular genetics.

[3]  G. Viglietto,et al.  Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. , 1996, Human molecular genetics.

[4]  John Bourke,et al.  Managing Duchenne muscular dystrophy – The additive effect of spinal surgery and home nocturnal ventilation in improving survival , 2007, Neuromuscular Disorders.

[5]  Paul T Martin,et al.  Congenital muscular dystrophies involving the O-mannose pathway. , 2007, Current molecular medicine.

[6]  I. Graham,et al.  Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. , 2007, Human gene therapy.

[7]  M. Leppert,et al.  Congenital muscular dystrophy with rigid spine syndrome: A clinical, pathological, radiological, and genetic study , 2000, Annals of neurology.

[8]  D. Troost,et al.  A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement , 1996, Annals of neurology.

[9]  Andrew G Engel,et al.  Mutations in myotilin cause myofibrillar myopathy , 2004, Neurology.

[10]  N. Clarke,et al.  SEPN1: Associated with congenital fiber‐type disproportion and insulin resistance , 2006, Annals of neurology.

[11]  J. Schessl,et al.  Novel ANO5 mutations causing hyper‐CK‐emia, limb girdle muscular weakness and miyoshi type of muscular dystrophy , 2012, Muscle & nerve.

[12]  F. Zara,et al.  POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. , 2007, Biochemical and biophysical research communications.

[13]  Robert H. Brown,et al.  Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer , 2012, PloS one.

[14]  T. Stojkovic,et al.  ColVI myopathies: where do we stand, where do we go? , 2011, Skeletal Muscle.

[15]  E. Bertini,et al.  Cyclosporine A in Ullrich Congenital Muscular Dystrophy: Long-Term Results , 2011, Oxidative medicine and cellular longevity.

[16]  C. Wijmenga,et al.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy , 1992, Nature genetics.

[17]  C. Wijmenga,et al.  High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. , 1995, American journal of human genetics.

[18]  K. Wagner,et al.  Loss of myostatin attenuates severity of muscular dystrophy in mdx mice , 2002, Annals of neurology.

[19]  M. Gregas,et al.  Serum Transaminase Levels in Boys With Duchenne and Becker Muscular Dystrophy , 2011, Pediatrics.

[20]  A. Pestronk,et al.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy , 2011, Neurology.

[21]  M. Hauser,et al.  Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy , 2012, Nature Genetics.

[22]  I. Ferrer,et al.  Myotilinopathy: refining the clinical and myopathological phenotype. , 2005, Brain : a journal of neurology.

[23]  H. Tabandeh.  Retinal vascular abnormalities in aortic coarctation , 1996, Eye.

[24]  Nicolas Deconinck,et al.  Expression of full-length utrophin prevents muscular dystrophy in mdx mice , 1998, Nature Medicine.

[25]  M. Ōsawa,et al.  Congenital progressive muscular dystrophy of the fukuyama type — clinical, genetic and pathological considerations — , 1981, Brain and Development.

[26]  Mark T Rogers,et al.  Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy , 2002, Neuromuscular Disorders.

[27]  R. Griggs,et al.  Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. , 1996, Annals of neurology.

[28]  A. Geurts,et al.  Strength training and aerobic exercise training for muscle disease. , 2013, The Cochrane database of systematic reviews.

[29]  J. Beckmann,et al.  Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies) , 2000, Neuromuscular Disorders.

[30]  M. Leppert,et al.  Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy , 2001, Neuromuscular Disorders.

[31]  E. Bertini,et al.  Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Wijmenga,et al.  Facioscapulohumeral muscular dystrophy in early childhood. , 1994, Archives of neurology.

[33]  J. Mendell,et al.  Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. , 2012, The American journal of cardiology.

[34]  R. Wuebbles,et al.  Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. , 2012, The American journal of pathology.

[35]  W. Modell.  On the significance of significant , 1981, The New England journal of medicine.

[36]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[37]  Daniel G. Miller,et al.  A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy , 2010, Science.

[38]  J. Mendell,et al.  Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease , 2009, Muscle & nerve.

[39]  J. Beckmann,et al.  A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B , 1998, Nature Genetics.

[40]  Livija Medne,et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.

[41]  K. Mathews,et al.  Collagen VI glycine mutations: Perturbed assembly and a spectrum of clinical severity , 2008, Annals of neurology.

[42]  R. Abresch,et al.  Profiles of neuromuscular diseases. Becker's muscular dystrophy. , 1995, American journal of physical medicine & rehabilitation.

[43]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[44]  T. Brüning,et al.  Homozygous mutations in caveolin‐3 cause a severe form of rippling muscle disease , 2003, Annals of neurology.

[45]  E. Bertini,et al.  Congenital Muscular Dystrophies: A Brief Review , 2011, Seminars in pediatric neurology.

[46]  J. Mendell,et al.  Three‐tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD) , 2004, Human mutation.

[47]  N. Urgancı,et al.  Incidental raised transaminases: a clue to muscle disease , 2006, Annals of tropical paediatrics.

[48]  J. Mendell,et al.  Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.

[49]  K. Bushby,et al.  Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports , 1998, Neuromuscular Disorders.

[50]  K. Flanigan,et al.  Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens , 2012, Neuropathology and applied neurobiology.

[51]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[52]  A. Pestronk,et al.  Exome sequencing reveals DNAJB6 mutations in dominantly‐inherited myopathy , 2012, Annals of neurology.

[53]  J. Mendell,et al.  RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  P. Harper,et al.  Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD) , 1995, Human molecular genetics.

[55]  B. Alman,et al.  Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade , 2006, Neuromuscular Disorders.

[56]  R. Weiss,et al.  Autosomal recessive inheritance of classic Bethlem myopathy , 2009, Neuromuscular Disorders.

[57]  O. F. Brouwer,et al.  Hearing loss in facioscapulohumeral muscular dystrophy , 1991, Neurology.

[58]  I. Nonaka,et al.  Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses , 1995, Muscle & nerve. Supplement.

[59]  M. Camboni,et al.  Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice. , 2009, The American journal of pathology.

[60]  F. Muntoni,et al.  Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. , 2002, American journal of human genetics.

[61]  R. Ahima,et al.  Functional improvement of dystrophic muscle by myostatin blockade , 2002, Nature.

[62]  J. Beckmann,et al.  β–sarcoglycan: characterization and role in limb–girdle muscular dystrophy linked to 4q12 , 1995, Nature Genetics.

[63]  J. Yoon,et al.  Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. , 2007, The American journal of pathology.

[64]  B. Alman,et al.  Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols , 2004, Neuromuscular Disorders.

[65]  M. Tarnopolsky,et al.  Clinical features of facioscapulohumeral muscular dystrophy 2 , 2010, Neurology.

[66]  Susan C. Brown,et al.  Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. , 2007, Brain : a journal of neurology.

[67]  F. Baas,et al.  Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). , 2000, Human molecular genetics.

[68]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[69]  B. Byrne,et al.  Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2D , 2010, Annals of neurology.

[70]  J. Weissenbach,et al.  Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. , 1995, Nature genetics.

[71]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[72]  F. Hanefeld,et al.  Desmin‐related myopathy with mallory body–like inclusions is caused by mutations of the selenoprotein N gene , 2004, Annals of neurology.

[73]  K. Bushby,et al.  Collagen VI related muscle disorders , 2005, Journal of Medical Genetics.

[74]  H. Topaloglu,et al.  An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker–Warburg syndrome (WWS) caused by a mutation in the POMT1 gene , 2005, Neuromuscular Disorders.

[75]  D. Escolar,et al.  Congenital muscular dystrophies. , 2011, Handbook of clinical neurology.

[76]  R. Finkel,et al.  DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy , 2008, Annals of neurology.

[77]  G. V. Ommen,et al.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy , 2003, Nature Genetics.

[78]  M. Nigro,et al.  Beevor's sign and facioscapulohumeral dystrophy. , 1990, Archives of neurology.

[79]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[80]  Colin Chandler,et al.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation , 2002, Neuromuscular Disorders.

[81]  Susan C. Brown,et al.  Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. , 2008, Archives of neurology.

[82]  F. Baas,et al.  Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. , 2010, American journal of human genetics.

[83]  J. Beckmann,et al.  The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12–14, 2002 , 2003, Neuromuscular Disorders.

[84]  K. Arimura,et al.  Frameshift mutation in the collagen VI gene causes Ullrich's disease , 2001, Annals of neurology.

[85]  M. Schwartz,et al.  LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype , 2005, Neurology.

[86]  L. Kunkel,et al.  Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy , 1995, Science.

[87]  J. Bach,et al.  Duchenne Muscular Dystrophy: The Effect of Glucocorticoids on Ventilator Use and Ambulation , 2010, American journal of physical medicine & rehabilitation.

[88]  E. Bakker,et al.  Inter- and intrachromosomal sub-telomeric rearrangements on 4q35: implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. , 1998, Human molecular genetics.

[89]  M. Main,et al.  Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials , 2010, Neuromuscular Disorders.

[90]  F. Muntoni,et al.  Immunohistological intensity measurements as a tool to assess sarcolemma‐associated protein expression , 2009, Neuropathology and applied neurobiology.

[91]  F. Muntoni,et al.  Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human , 2007, Neuromuscular Disorders.

[92]  H. Bécane,et al.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. , 2005, Journal of the American College of Cardiology.

[93]  J. T. Dunnen,et al.  Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort , 2005, American journal of medical genetics. Part A.

[94]  Carol J. Saunders,et al.  DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy , 2009, Neuromuscular Disorders.

[95]  G. Comi,et al.  Congenital muscular dystrophies with defective glycosylation of dystroglycan , 2009, Neurology.

[96]  L. Merlini,et al.  Early prednisone treatment in Duchenne muscular dystrophy , 2003, Muscle & nerve.

[97]  C. Angelini,et al.  Molecular and muscle pathology in a series of caveolinopathy patients , 2005, Human mutation.

[98]  K. North,et al.  Diagnosis and etiology of congenital muscular dystrophy , 2008, Neurology.

[99]  M. Main,et al.  SEPN1-related myopathies , 2011, Neurology.

[100]  F. Zara,et al.  Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy , 1998, Nature Genetics.

[101]  P. Guicheney,et al.  Selenoprotein N in skeletal muscle: from diseases to function , 2012, Journal of Molecular Medicine.

[102]  J. Mendell,et al.  Rapid direct sequence analysis of the dystrophin gene. , 2003, American journal of human genetics.

[103]  R. Tawil,et al.  Facioscapulohumeral muscular dystrophy , 2006, Muscle & nerve.

[104]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.

[105]  F. Baas,et al.  Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures , 1996, Nature Genetics.

[106]  Susan C. Brown,et al.  Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. , 2001, American journal of human genetics.

[107]  F. Muntoni,et al.  Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome , 2001, Nature Genetics.

[108]  J. Mendell,et al.  Gene therapy for muscular dystrophy: Lessons learned and path forward , 2012, Neuroscience Letters.

[109]  E. Bertini,et al.  Phenotypic clustering of lamin A/C mutations in neuromuscular patients , 2007, Neurology.

[110]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[111]  J. Bodensteiner,et al.  Facioscapulohumeral muscular dystrophy: The choice of a biopsy site , 1986, Muscle & nerve.

[112]  M. Claustres,et al.  An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. , 2006, Human molecular genetics.

[113]  J. Mendell,et al.  Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. , 2009, American journal of physiology. Cell physiology.

[114]  I. Nonaka,et al.  Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan , 2007, Neurology.

[115]  K. Bushby,et al.  Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy , 2005, Journal of Medical Genetics.

[116]  A. Bird,et al.  Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. , 1987, Brain : a journal of neurology.

[117]  J. Beckmann,et al.  Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy , 1994, Cell.

[118]  K. Campbell,et al.  LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies , 2004, Nature Medicine.

[119]  Cindy Hamil,et al.  Evidence‐based path to newborn screening for duchenne muscular dystrophy , 2012, Annals of neurology.

[120]  Isabelle Richard,et al.  Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A , 1995, Cell.

[121]  S. Harper,et al.  DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53‐dependent myopathy in vivo , 2011, Annals of neurology.

[122]  J. Mendell,et al.  Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophy , 2010, Annals of neurology.

[123]  K. Bushby,et al.  A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. , 2011, Brain : a journal of neurology.

[124]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[125]  J. Mendell,et al.  Gene Therapy for Duchenne Muscular Dystrophy: Expectations and Challenges , 2007 .

[126]  K. Bushby,et al.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.

[127]  A. Aloysius,et al.  Natural history of Ullrich congenital muscular dystrophy , 2009, Neurology.

[128]  G. Valle,et al.  Dysferlin protein analysis in limb-girdle muscular dystrophies , 2007, Journal of Molecular Neuroscience.

[129]  M. Vorgerd,et al.  Variable reduction of caveolin-3 in patients with LGMD2B/MM , 2003, Journal of Neurology.